The risk of infection for CLL patients receiving idelalisib
Prognostic markers for CLL - how do they help determine who gets which treatment?
Idelalisib plus bendamustine and rituximab improves the outcome of relapsed/refractory CLL
The stratification of CLL patients and implications for clinical practice
What can clonal evolution in chronic lymphocytic leukemia (CLL) tell us about outcomes?